Anlon Healthcare is trading at RS 142.93, up by 8.50 points or 6.32% from its previous close of RS 134.43 on the BSE.

The stock opened at RS 136.70 and touched a high of RS 147.80 and a low of RS 132.00 during the session. So far, 1,71,319 shares have been traded on the counter.

The BSE group 'B' stock with a face value of RS 10 has recorded a 52-week high of RS 147.80 on 22-Sep-2025 and a 52-week low of RS 86.98 on 05-Sep-2025. Over the past week, the scrip has seen a high of RS 147.80 and a low of RS 106.30. The company’s current market capitalization stands at RS 769.53 crore.

Promoters hold 52.68% of the company’s shares, while institutions and non-institutions hold 18.77% and 28.55%, respectively.

Anlon Healthcare has developed two new anti-malarial products—Artemether and Lumefantrine—and plans to launch both by November 2025. This move supports the company’s strategy to expand its product portfolio and meet growing market demand.

Anlon Healthcare is a chemical manufacturing firm engaged in producing pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for customers in India and global markets.